Background. Currently there is no consensus on the use of adjuvant radiotherapy (RT) in retroperitoneal sarcoma (RPS). We have analysed clinical outcomes in patients with localised RPS treated at two Scandinavian Sarcoma Group (SSG) centres: Haukeland University Hospital (HUH), Bergen, Norway and Skane University Hospital (SUH), Lund, Sweden to clarify the effects of adjuvant RT on local control and overall survival (OS). Material and methods. Local databases and registers at HUH and SUH as well as the SSG central register were used to identify RPS patients. Patients with localised RPS who underwent surgery in Bergen between 1988 and 2009 and in Lund from 1998 to 2009 were included. Medical records were examined for clinical data, tumour ch...
Abstract Background Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important compo...
Background. This study aimed to investigate changes in treatment strategy and outcome for patients w...
Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and e...
Abstract Background Adjuvant therapy is a promising treatment to improve the prognosis of cancer pat...
Purpose. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation t...
Retroperitoneal sarcomas (RPS) are rare tumours that typically present late and carry a poor prognos...
Abstract Retroperitoneal sarcomas (RPS) are rare tumours that typically present late and carry a poo...
Locoregional recurrence (LRR) is the predominant pattern of relapse and often the cause of death in ...
Abstract Background Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has ...
BACKGROUND: Several unanswered questions surround the management of retroperitoneal sarcoma (RPS). G...
Purpose. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation t...
Background and purpose: Contemporary data regarding the benefit of radiotherapy in surgically treate...
Perioperative radiation therapy (RT) has been associated with reduced local recurrence in patients w...
Retroperitoneal sarcomas (RPS) are rare cancers whose management can be challenging due to various p...
Purpose Retroperitoneal sarcomas (RPS) are rare tumours with an annual reported incidence of 2.7 per...
Abstract Background Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important compo...
Background. This study aimed to investigate changes in treatment strategy and outcome for patients w...
Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and e...
Abstract Background Adjuvant therapy is a promising treatment to improve the prognosis of cancer pat...
Purpose. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation t...
Retroperitoneal sarcomas (RPS) are rare tumours that typically present late and carry a poor prognos...
Abstract Retroperitoneal sarcomas (RPS) are rare tumours that typically present late and carry a poo...
Locoregional recurrence (LRR) is the predominant pattern of relapse and often the cause of death in ...
Abstract Background Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has ...
BACKGROUND: Several unanswered questions surround the management of retroperitoneal sarcoma (RPS). G...
Purpose. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation t...
Background and purpose: Contemporary data regarding the benefit of radiotherapy in surgically treate...
Perioperative radiation therapy (RT) has been associated with reduced local recurrence in patients w...
Retroperitoneal sarcomas (RPS) are rare cancers whose management can be challenging due to various p...
Purpose Retroperitoneal sarcomas (RPS) are rare tumours with an annual reported incidence of 2.7 per...
Abstract Background Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important compo...
Background. This study aimed to investigate changes in treatment strategy and outcome for patients w...
Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and e...